INTRODUCTION
============

Inflammatory bowel diseases (IBDs) are chronic disabling gastrointestinal disorders affecting every aspect of the affected person\'s life, and account for substantial costs to the health-care system and society.[@B1] With the growing number of patients with IBD and cases of hospitalization, the overall medical care cost consequently increases considerably. The annual hospitalization cost per patient, cost per hospitalization, and daily cost during hospitalization have increased significantly in the past decade (all *P* \<0.001).[@B2] The increased hospitalization costs of IBD patients may be associated with biologics use, length of hospital stay, medical insurance, subtypes of IBD, prognostic factors, surgery, and endoscopy.[@B2]

The cost of caring for IBD patients is high, with the annual mean cost of around US \$6,000 to US \$8,000 for CD patients, and US \$4,000 to US \$5,000 for UC patients in Germany (2006--2007) and the United States (2003--2004).[@B3][@B4] Results from a large European inception cohort study, enrolling 1,321 patients with IBD diagnosed from October 1991 to September 1993, showed that the mean annual total expenditure on health care was €1,871 per patient-year (equating to approximately US \$2,476 per patient-year) for IBD.[@B5] The most expensive aspects were medical and surgical hospitalizations, together accounting for 63% of the cost in CD and 45% in UC.

Recent studies demonstrated that the use of anti--tumor necrosis factor (TNF) therapy may be associated with a reduced need for surgery and hospitalization, as well as an improvement in the quality of life and work productivity in both CD and UC patients.[@B6] There is an apparent shift in cost profile from surgery and hospitalization toward anti-TNF treatment; however, the relatively consistent overall costs suggest that the high costs of these drugs are partly compensated for by a reduction in surgery and hospitalization rates.

Without government support, the cost burden of caring for IBD patients will unavoidably rest on the patients and their family. However, if the government will provide full support, it will place a large financial burden on the health-care systems of the country. With the increasing incidence and prevalence of IBD, as well as the use of more and more biologics and state-of-the-art techniques in treating or monitoring IBD patients, how and to what extent public medical insurance support affects current IBD management becomes a practical issue. In this report, we compare the differences in public medical insurance systems for IBD patients among Asian countries, and try to build a basis for understanding the differences and limitations in treating IBD patients among different countries.

METHODS
=======

Questionnaires were designed to gather (i) general, (ii) diagnosis, (iii) treatment, (iv) disease monitoring, and (v) management information, as well as to inquire about the availability of public health systems, the costs of medical, diagnostic, and endoscopy expense, and the coverage rate of biologics use. The questionnaires were sent to IBD experts in each of the Asian countries studied. The results were summarized according to feedback from the responders. The summarized results were returned for review and approval by the responding IBD experts from each country.

RESULTS
=======

We collected responses from Japan (Dr. Tadakazu Hisamatzu), South Korea (Dr. Hyun-Soo Kim), China (Dr. Bayasi Guleng), Hong Kong (Dr. Siew C. Ng), Singapore (Dr. Khoon Lin Ling), Malaysia (Dr. Ida Hilmi), and India (Dr. Vineet Ahuja) in June 2014. The responses were combined with the results from Taiwan, and summarized as the overall results for this report.

1. General Information
----------------------

As shown in [Table 1](#T1){ref-type="table"}, the public health insurance coverage rate is high in Taiwan, Japan, South Korea, China, Hong Kong, and Singapore but low in Malaysia and India. Patients could consult a gastroenterologist or colorectal surgeon by either the walk-in or referral system for the diagnosis and treatment of their IBD in all of these countries. A registration system is available in Taiwan, Japan, South Korea, and Hong Kong. In these countries, registered IBD patients could obtain good support from the government, with their own expenses for treatment being zero (Japan) to minimal (Taiwan, South Korea, and Hong Kong). In Singapore, the copayment rate ranges from 10% to 90%. In Malaysia, payment for general care is low and does not include biologics. In India, most patients are treated in private service hospitals, with the patients themselves shouldering the entire medical expense.

2. Diagnosis
------------

As shown in [Table 2](#T2){ref-type="table"}, among the diagnostic endoscopy methods, capsule endoscopy is the most expensive (from US \$500 to US \$2,800), except in Japan where the cost of capsule endoscopy is covered by the government. The most common tool for diagnosing IBD, ileocolonoscopy, was mostly free except in Singapore (about US \$750) and India (about US \$100).

3. Treatment
------------

As summarized in [Table 3](#T3){ref-type="table"}, conventional therapies (5-aminosalicylic acid, steroid, immunomodulators) are paid for by public health insurance in Taiwan, Japan, China, and Hong Kong; in Korea, a 10% copayment system is established. Conventional therapies are paid for by patients in Singapore, Malaysia, and India, and the cost is higher in Singapore than in India. In Japan, biologics are paid for by the government, without a need for prior approval and without a time limitation. In South Korea, patients are responsible for a 10% copayment for biologics. In Taiwan and Hong Kong, the use of biologics needs to be approved in advance to be eligible for a reimbursement. Patients have to pay for biologics in China, Singapore, Malaysia (except civil servants), and India. The cost is between US \$15,000 to US \$25,000 per patient per year.

4. Monitoring
-------------

Tests for complete blood cell count, CRP, ESR, and serum biochemistry for the follow-up of IBD patients are covered by the government or minimally paid for by the patients in all of the countries studied ([Table 4](#T4){ref-type="table"}). Fecal calprotectin test is available in clinical practice in Singapore and India, costing about US \$40 to US \$80. It is available for research purposes in Taiwan, Japan, South Korea, and Malaysia; however, it is not yet available in China and Hong Kong. Tests for TNF-α antibody titer and the antibody to TNF-α antibody are not yet available in all these countries.

5. Risk Management
------------------

Hepatitis B screening is covered by public health insurance in Taiwan, Japan, China, Hong Kong, and Malaysia. In South Korea, Singapore, and India, patients themselves have to pay for hepatitis B screening (US \$10--25). *Mycobacterium tuberculosis* screening and monitoring are bundled with TNF-α treatment in Taiwan; covered by the government in Japan; and paid for by patients in South Korea (10% copayment), China, Hong Kong, Singapore, Malaysia, and India (US \$50--260). Thiopurine S-methyltransferase (TPMT) genotyping/activity and thiopurine metabolite assays are only available in India and cost about US \$100. Vaccination programs are free for registered IBD patients in Taiwan, as well as in China and Hong Kong. In other countries, patients have to pay for vaccination ([Table 5](#T5){ref-type="table"}).

6. Possible Impact
------------------

The above results are in line with the previous reports stating that the cost is mostly related to medical expenses, especially biologics. We hypothesized that the percentages of IBD patients taking biologics would be different between countries with a high and those with a low public health coverage. Indeed, we found that the percentage of CD patients treated with biologics was as high as 30%--40% in Japan, where the government covers all expenses for IBD patients. The percentage maybe as low as 1% for CD patients in India, where most of the patients have to pay for the biologics themselves ([Table 6](#T6){ref-type="table"}).

As reports on mortality results are available only from Japan and Taiwan, and biologics only became available for clinical use in Taiwan in 2008, it might be too early to draw any conclusion about public health insurance--related mortality in IBD patients in these Asian countries.

DISCUSSION
==========

From this survey, we found that there were differences in the public health insurance systems among Asian countries. This probably affected the proportion of patients who need to be treated with more expensive medications such as the biologics. Japan and India are the two extremes for this situation. The percentage of IBD patients taking biologics is highest in Japan, where the payment for the diagnosis, treatment, and monitoring of IBD is entirely covered by the government. In contrast, the percentage of IBD patients taking biologics is lowest in India, where the coverage rate by public health insurance is low and IBD patients have to pay for most of their medical expenses. As biologics have been proven to improve the clinical and mucosal status of IBD patients,[@B7] determining whether the difference will affect the outcomes (such as operation rate, admission rate, or even mortality rate) needs a longer period of follow-up.

This report has some limitations. First, not all IBD experts in the Asian countries studied replied to the survey. Second, those who did reply were limited in number, and thus might not be representative of the true situation in each country. Third, no surgical rate, admission rate, and mortality results were available from all the countries. Therefore, this report could function as an initial report providing background information for understanding the differences in the treatment of IBD patients among countries in Asia.

In summary, this is the first report to compare the public health insurance systems in Asia, especially focusing on IBD-related diagnosis and treatment. The effect derived from the differences needs a longer period of observation to allow making a firm conclusion.
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###### General Information of the Public Health Insurance in Asia

![](ir-14-218-i001)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                             Taiwan                                                                      Japan                           South Korea             China           Hong Kong                                                                    Singapore          Malaysia                               India
  ------------------------------------ --------------------------------------------------------------------------- ------------------------------- ----------------------- --------------- ---------------------------------------------------------------------------- ------------------ -------------------------------------- ----------------------------
  Public health insurance cover rate   99%                                                                         \>90%                           100%                    \>95%           92%                                                                          100%               \<5%                                   \<5%

  Access to GI/CRS specialist          Walk in/Refer                                                               Walk in/Refer                   Walk in/Refer           Walk in/Refer   Walk in/Refer                                                                Walk in/Refer      Walk in/Refer                          Walk in/Refer

  General cost for IBD patients        Registered cases In patients: free (except some medications/examinations)   Registered cases: free          Registered cases: 10%   Free            Registered cases In patients: free (except some medications/examinations)    Co-pay: 10%--90%   Minimal pay (except expensive drugs)   Government hospital: free\
                                                                                                                                                                                                                                                                                                                                  Private: have to pay

                                       Registered cases Out patients: free                                                                                                                 Registered cases Out patients: free (except some medications/examinations)                                                             

                                       Non-registered cases: pay 5%--10%                                           Non-registered cases: pay 30%                                           Non-registered cases: pay 5%--10%                                                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GI/CRS, gastroenterology/colorectal surgeon.

###### Comparison of the Cost for IBD Diagnostic Tools in Asia
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  Diagnosis (in US dollars)   Taiwan                      Japan   South Korea                 China    Hong Kong                   Singapore                         Malaysia                 India
  --------------------------- --------------------------- ------- --------------------------- -------- --------------------------- --------------------------------- ------------------------ -------
  EGD                         Free                        Free    10% of US dollars 50/30     Free     Free                        300                               Free to minimal charge   50
  Colonoscopy                 Free                        Free    10% of US dollars 80/50     Free     Free                        750                               Free to minimal charge   100
  Small bowel scopet          Free except the over tube   Free    700--1,200                  Co-pay   Free except the over tube                                     Free to minimal charge   100
  Over tube                   630--1,200                  Free    600                         130      400                         1,000--2,500                      Free to minimal charge   200
  Anesthesia                  100--500                    Free    Free                        Free     Free                        extra                             Free to minimal charge   Extra
  Capsule endoscopy           1,500                       Free    700                         565      2,000                       1,800 (public); 2,800 (private)   1000                     500
  CT/MRI                      Free                        Free    10% of 160 (CT)/600 (MRI)   Free     Free                        500--1,000                        Free to minimal charge   200

EGD, esophagogastroduodenoscopy

###### Comparison of the Cost for IBD Treatment in Asia
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  Treatment (annual cost: US dollars)   Taiwan                                Japan   South Korea   China    Hong Kong                             Singapore    Malaysia                                                            India
  ------------------------------------- ------------------------------------- ------- ------------- -------- ------------------------------------- ------------ ------------------------------------------------------------------- ----------------
  Non-biologics                                                                                                                                                                                                                     
   5-ASA                                Free                                  Free    10% co-pay    Free     Free                                  600--1,200   1,000--1,500, free for civil servants                               50
   Steroid                              Free                                  Free    10% co-pay    Free     Free                                  300--600     Free for civil servants, minimal charge for paying patients         10
   Azathioprine                         Free                                  Free    10% co-pay    Free     Free                                  600--1,200   300 USD for paying patients, free for civil servants                50
  Biologics                                                                                                                                                                                                                         
   TNF-α antibody                       Approved: free Not approved: 17,000   Free    10% co-pay    15,000   Approved: free Not approved: 15,000   25,000       20,000 for paying patients, pay and claim back for civil servants   20,000--22,000

5-ASA, 5-aminosalicylic acid; TNF, tumor necrosis factor.

###### Comparison of the Cost for IBD Monitoring Tools in Asia
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  Monitoring                     Taiwan          Japan           South Korea     China   Hong Kong   Singapore   Malaysia        India
  ------------------------------ --------------- --------------- --------------- ------- ----------- ----------- --------------- -------
  CBC/CRP/ESR/Biochemistry       Free            Free            10% of 35/15    Free    Free        40--80      Free            20
  Fecal calprotectin             Research only   Research only   Research only   NA      NA          40--80      Research only   60
  TNF-α Ab titer; Ab to TNF-Ab   NA              NA              NA              NA      NA          NA          NA              NA

CBC, complete blood cell count; NA, not available; TNF, tumor necrosis factor.

###### Comparison of the Cost for IBD Risk Management in Asia
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  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Risk management (cost: US dollars)         Taiwan                          Japan   South Korea   China     Hong Kong              Singapore   Malaysia   India
  ------------------------------------------ ------------------------------- ------- ------------- --------- ---------------------- ----------- ---------- -------
  Hepatitis B screen                         Free                            Free    100% co-pay   Free      Free                   10--20      Free       25

  TB Quantiferon Gold/Tuberculin skin test   Bundled to TNF-α Ab treatment   Free    10% of 15     3 (PPD)   If research free/260   50--100     100        60

  TPMT genotype/Activity metabolites assay   NA                              NA      NA            NA        NA                     NA          NA         100

  Vaccination\                               Free to registered cases        30      15;\          Free      Free                   20          20         75
  (for example, Influenza)                                                           100% co-pay                                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

TB, tuberculosis; TNF, tumor necrosis factor; PPD, purified protein derivative; TPMT, Thiopurine S-methyltransferase; NA, not available.

###### Possible Impacts Derived From the Differences of Public Health Insurance in Asia
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  Possible impact                            Taiwan                                                                                    Japan                              South Korea   China     Hong Kong   Singapore   Malaysia   India
  ------------------------------------------ ----------------------------------------------------------------------------------------- ---------------------------------- ------------- --------- ----------- ----------- ---------- ----------------------------------------------
  \% of CD patients treated with biologics   25--30                                                                                    30--40                             20            \<10      15.4        10--15      25--30     1 (5%--10% indicated but only 1% affordable)
  \% of UC patients treated with biologics   Not approved by NHI yet (\<1, paid by patients)                                           10                                 2.2           \<5       1.4         5           5--10      Even less
  Mortality rate of IBD patients             Higher than Western Countries/ Japan                                                      Similar to Western countries       No data       No data   No data     No data     No data    No data
                                             SMR: 4.97 (3.72--6.63) for CD; 1.78 (1.46--2.17) for UC, from 1998 to 2008 in Taiwan^8^   SMR: 1.43 (0.53--3.12) for CD^9^                                                              

NHI, national health insurance; SMR, standardized mortality ratio.
